Overview

A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The study was a double-blind, placebo-controlled, crossover study to evaluate the efficacy of roflumilast on airway inflammation and function in patients with allergen-induced asthma. Individuals with stable, mild to moderate allergic asthma, with a history of episodic wheeze and shortness of breath, were eligible for enrollment.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca